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Objective. To evaluate the performance of a first trimester aneuploidy screening program for preeclampsia (PE) prediction in a
Portuguese obstetric population, when performed under routine clinical conditions.Materials and Methods. Retrospective cohort
study of 5672 pregnant women who underwent routine first trimester aneuploidy screening in a Portuguese university hospital
from January 2009 to June 2013. Logistic regression-based predictivemodels were developed for prediction of PE based onmaternal
characteristics, crown-rump length (CRL), nuchal translucency thickness (NT), andmaternal serum levels of pregnancy-associated
plasma protein-A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (free 𝛽-hCG). Results. At a false-positive
rate of 5/10%, the detection rate for early-onset (EO-PE) and late-onset (LO-PE) PE was 31.4/45.7% and 29.5/35.2%, respectively.
Although both forms of PE were associated with decreased PAPP-A, logistic regression analysis revealed significant contributions
from maternal factors, free 𝛽-hCG, CRL, and NT, but not PAPP-A, for prediction of PE. Conclusion. Our findings support that
both clinical forms of EO-PE and LO-PE can be predicted using a combination of maternal history and biomarkers assessed at first
trimester aneuploidy screening. However, detection rates weremodest, suggesting that models need to be improved with additional
markers not included in the current aneuploidy screening programs.
1. Introduction
Preeclampsia (PE) is a prevalent clinical entity in pregnancy,
which is responsible for substantial maternal-fetal morbidity
and mortality [1–4]. Prediction of PE could offer a window
of opportunity for intervention during pregnancy, making it
potentially possible to prevent adverse obstetric and neonatal
outcomes.
In the United Kingdom, the National Institute for Health
and Clinical Excellence (NICE) has delivered clinical guide-
lines recommending the evaluation of maternal risk factors
for PE at the first prenatal visit for all pregnant women [5].
However, screening for PE based only onmaternal history has
shown to be insufficient [6].
In this context, measurement in early pregnancy of a
variety of markers implicated in the pathophysiology of
PE has been proposed to predict its development. These
included tests for aneuploidy screening, renal and endothelial
dysfunction, oxidative stress, and fetal-derived products [7].
Because any single biomarker is unlikely to be effective in
prediction of the onset of a disorder as heterogeneous as PE,
it is under investigation which combinations of tests, such as
ultrasound and serum markers, would raise the effectiveness
of history and physical-based screening [7].
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Figure 1: Flow chart of the study population.
The accuracy ofmodels for PE prediction, eithermaternal
history-based or combined with biomarkers, is unknown in
the Portuguese population. Therefore, we aim to evaluate the
performance of a first trimester aneuploidy screening pro-
gram for preeclampsia prediction in a Portuguese obstetric
population, when performed under routine clinical condi-
tions.
2. Materials and Methods
2.1. Design, Setting, and Participants. This is a retrospective
cohort study of 5672 pregnant women who underwent rou-
tine first trimester aneuploidy screening in a Portuguese uni-
versity hospital (Centro Hospitalar do Porto) from January
2009 to June 2013. All singleton pregnancies between 9 weeks
and 0 days and 13 weeks and 6 days of gestation were consid-
ered for inclusion in the study. Cases of multiple pregnancy,
major fetal chromosomal or structural abnormalities,miscar-
riage, fetal death prior to 24 weeks, or loss of follow-up were
excluded (𝑛 = 873) (Figure 1). All participants were followed
from first trimester combined aneuploidy screening until
delivery. The study protocol has been approved by the local
ethics committee and institutional review boards.
2.2. Maternal Evaluation. Combined screening for aneuploi-
dies was performed between 9 weeks and 0 days and 13
weeks and 6 days of gestation (𝑛 = 4799). Participants
were asked to provide information on age, ethnicity, method
of conception, weight, smoking status, chronic conditions,
parity and previous pregnancy complications. Blood samples
were collected and maternal serum pregnancy-associated
plasma protein-A (PAPP-A) and free beta-subunit of human
chorionic gonadotropin (free 𝛽-hCG) were measured using
routine automated analyzers. During the study period, the
analytical platform used by the clinical chemistry laboratory
for measuring these biochemical markers was changed from
IMMULITE 2000 system (𝑛 = 1634) to DELFIA XPRESS
analyzer (𝑛 = 3165); this event was taken into consideration
in the statistical analysis of data. An ultrasound examination
was performed between 11 weeks and 0 days and 13 weeks
and 6 days of gestation, including themeasurement of crown-
rump length (CRL) and nuchal translucency thickness (NT);
gestational age was estimated on the basis of CRL measure-
ments. These clinical data were systematically collected into
an integrated electronic form in order to perform combined
first trimester risk assessment.
2.3. Outcome Measures. Data on pregnancy outcome were
collected frommaternal and pediatric records. PE cases were
defined by the new onset of hypertension (>140/90mmHg)
developed after 20 weeks of gestation in a woman with previ-
ously normal blood pressure, associated by coexisting signifi-
cant proteinuria, according to the definition of the American
College of Obstetricians and Gynecologists (ACOG) [3].
Chronic hypertension cases were defined as known high
blood pressure before conception or new onset of hyperten-
sion before 20 weeks of gestation [3]. In the cases in which
PE was superimposed on chronic hypertension, there was
significant proteinuria development after 20 weeks of gesta-
tion in women with known chronic hypertension [3]. Cases
of new onset of hypertension after 20 weeks of gestation in
the absence of accompanying proteinuria were considered as
gestational hypertension [3]. These outcome diagnoses were
made by the treating physician and registered in maternal
records at hospital discharge. Preeclampsia cases were classi-
fied as early-onset (EO-PE) or late-onset (LO-PE), depending
on when findings first become apparent, before or after 34
weeks of gestation. We also included obstetric and neonatal
outcomes in our analysis, such as gestational age at delivery,
delivery by cesarean section, stillbirth occurrence, and birth
weight.The adopted definition of lowbirthweight (LBW)was
birth weight below 2500 grams.
2.4. Statistical Analysis. A descriptive analysis of maternal
characteristics was conducted, separating the unaffected
group from the women affected by preeclampsia according
to their PE status, as described in the previous section. The
maternal weight, PAPP-A, and 𝛽-hCG were expressed as
multiples of the median (MoM) and log transformed for
logistic regression analysis. Considering that two distinct
analytical platforms were used for PAPP-A and 𝛽-hCG mea-
surement, we adjusted these differences by performing the
MoM transformation with the median values of the samples
of both assays. The MoM values distribution obtained by
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this procedure were not statistically different when compared
by analytical method using ANOVA analysis. We performed
Mann-Whitney 𝑈 Test and Pearson 𝜒2 for single categorical
and quantitative variables analysis across groups. Moreover,
the Kruskal-Wallis test was also used to compare the quan-
titative variables across multiples groups with subsequent
pairwise analysis.
ROC (Receiver Operating Characteristic) analysis was
performed to evaluate models performances and estimate
predictive values, which were presented as the estimated
detection rate (DR) at fixed false-positive rate (FPR) of 5%
and 10%.All the binomial logisticmodelswere obtained using
stepwise backward algorithm for variable selection and a 𝑃-
value cutoff of 0.05. We also presented the Nagelkerke 𝑅2 for
each model.
The statistical software package SPSS 21.0 [8] was used for
data analyses.
3. Results and Discussion
3.1. Results. First trimester aneuploidy screening was carried
out in 5672 pregnant women between January 2009 and June
2013.We excluded 873 cases because of missing outcome data
(𝑛 = 715) or pregnancies resulting in miscarriage, fetal death
prior to 24 weeks, or major fetal chromosomal or structural
abnormalities (𝑛 = 158).
In the remaining 4799 cases, 140 developed PE (2.9%) and
4659 were pregnancies unaffected by PE. In the PE group,
35 (25%) developed early-onset PE and 105 (75%) developed
late-onset PE. Biomarkers included in first trimester com-
bined aneuploidy screening were available in all cases. A
descriptive analysis of maternal characteristics, aneuploidy
screening biomarkers results, and pregnancy outcomes is
presented in Table 1.
In the PE group, compared to unaffected pregnancies,
there was a higher median maternal age and weight as well
as a higher prevalence of nulliparous women and history
of chronic hypertension or diabetes mellitus. There were
no significant differences in maternal ethnic origin, smok-
ing habits, type of conception and infant gender between
groups. In both the EO-PE and LO-PE groups PAPP-A were
lower compared to unaffected pregnancies; there were no
significant differences in free 𝛽-hCG, CRL, and NT. Median
gestational age at delivery was lower in PE group compared
to unaffected pregnancies and in EO-PE group compared
to LO-PE group. Delivery by cesarean section was carried
out in 70.5% of PE cases compared to 34.1% in pregnancies
unaffected by PE. There was a lower median birth weight in
PE group compared to unaffected pregnancies and in EO-
PE group compared to LO-PE group, as well as a higher
prevalence of LBW.
Although EO-PE and LO-PE were associated with
decreased PAPP-A (0.93 MoM and 0.85 MoM), logistic
regression analysis demonstrated that there were significant
contributions from maternal factors, free 𝛽-hCG, CRL and
NT, but not PAPP-A, for prediction of PE (Table 2). The 𝑅2
values obtained were 10.0%, 9.4%, and 10.3% for PE, EO-PE
and LO-PE, respectively. As expected, maternal history of
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Figure 2: ROC curves of logistic regression models for prediction
of PE, EO-PE, and LO-PE by maternal characteristics and aneu-
ploidy screening biomarkers. PE, preeclampsia; EO-PE, early-onset
preeclampsia; LO-PE, late-onset preeclampsia.
PE, chronic hypertension, or diabetes mellitus contributed
to the increase of the risk of PE, even when the last was not
found significant for early expression of the disease. Similarly,
higher maternal age and weight as well as nulliparous condi-
tion were also significant risk factors for PE.
Our logistic regressionmodels for PE prediction estimate
that 27.9%, 31.4%, and 29.5% of PE, EO-PE, and LO-PE cases,
respectively, could be detected with a 5% false-positive rate
(Table 3).Themodel for EO-PE prediction presented the best
performance (Figure 2), with detection rates of 31.4% and
45.7% at false-positive rates of 5% and 10%.
A univariate analysis of PAPP-A and free 𝛽-hCG accord-
ing to fetal weight at delivery shows lower median PAPP-
A in LBW group but no significant differences of free 𝛽-
hCG (Figure 3). Moreover, when we considered a logistic
regression model for LBW, including all the previous vari-
ables, the final obtained model is 1.886 − 1.013 (if chronic
hypertension) + 0.658 (if caucasian) − 0.570 (if smoker) +
0.196 (if multiparous) + 1.155∗ PAPP-A (MoM, Log) + 3.381∗
MaternalWeight (MoM, Log).This suggests that, unlike in PE
prediction models, PAPP-A is related to LBW when other
variables are included in a logistic regression model.
3.2. Discussion. Our cohort study of 4799 pregnant women
who underwent routine first trimester aneuploidy screening
in a Portuguese university hospital found a prevalence of PE
of 2.9%, which is consistent with the reported epidemiologic
data available in the literature [1–4, 9–11].
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Table 1: Demographic characteristics of the study population.
Variable Unaffected pregnancy(𝑛 = 4659) PE (𝑛 = 140) EO-PE (𝑛 = 35) LO-PE (𝑛 = 105)
Maternal age, years, median (IQR)∗a 29.9 (25.8–33.0) 31.0 (27.7–33.6) 30.0 (25.0–34.9) 31.0 (28.0–33.0)
Maternal weight, median (IQR)
Kg∗a 63.5 (57.0–72.0) 70.0 (60.9–82) 73.0 (64.5–82.0) 69.3 (60.6–83.4)
MoM∗a 0.99 (0.89–1.13) 1.10 (0.95–1.28) 1.14 (1.01–1.28) 1.07 (0.94–1.30)
Ethnicity, 𝑛 (%)
White 4529 (97.2) 138 (98.6) 34 (97.1) 104 (99.0)
Black 82 (1.8) 1 (0.7) 1 (2.9) 0 (0.0)
Other 48 (1.0) 1 (0.7) 0 (0.0) 1 (1.0)
Nulliparous, 𝑛 (%)b 2843 (61.0) 98 (70.0) 27 (77.1) 71 (67.6)
Medical history, 𝑛 (%)
Chronic hypertensionb 104 (2.2) 12 (8.6) 5 (14.3) 7 (6.7)
Renal disease 5 (0.1) 1 (0.7) 1 (2.9) 0 (0.0)
Diabetes mellitusb 47 (1.0) 9 (6.4) 1 (2.9) 8 (7.6)
Smoking during pregnancy, 𝑛 (%) 975 (20.9) 21 (15.0) 6 (17.1) 15 (14.3)
Spontaneous conception, 𝑛 (%) 4486 (96.3) 130 (92.9) 33 (94.3) 97 (92.4)
Ultrasound markers, median (IQR)
CRL, mm 62.9 (56–70) 64.5 (58–70) 63.2 (56–68.9) 65.0 (59–70.5)
NT, mm 1.5 (1.2–1.8) 1.5 (1.2–1.8) 1.5 (1.2–1.9) 1.5 (1.1–1.8)
Maternal serum, median (IQR)
PAPP-A, MoM∗a 1.01 (0.63–1.60) 0.85 (0.56–1.35) 0.93 (0.33–1.39) 0.85 (0.58–1.33)
Free 𝛽-hCG, MoM 1.00 (0.66–1.54) 1.10 (0.66–1.64) 0.93 (0.53–1.38) 1.17 (0.70–1.76)
Obstetric outcomes
Gestational hypertension, 𝑛 (%) 57 (1.2) 0 (0.0) 0 (0.0) 0 (0.0)
Cesarean section, 𝑛 (%)b 1589 (34.1) 98 (70.5) 31 (88.6) 67 (64.4)
Gestational age at delivery, weeks, median (IQR)∗𝑎 39 (38–40) 37 (35–38) 34 (29–36) 37 (36–39)
Neonatal outcomes
Male, 𝑛 (%) 2367 (50.8) 67 (48.2) 19 (54.3) 48 (46.2)
Stillbirth, 𝑛 (%) 14 (0.3) 2 (1.4) 2 (5.7) 0 (0.0)
Birth weight, g, median (IQR)∗a 3165 (2873–3440) 2670 (2150–3055) 1910 (1050–2440) 2830 (2481–3158)
LBW, 𝑛 (%)b 354 (7.6) 55 (39.6) 27 (77.1) 28 (26.9)
PE: preeclampsia; EO-PE: early-onset preeclampsia; LO-PE: late-onset preeclampsia; IQR: interquartile range; CRL: crown-rump length; NT: nuchal
translucency thickness; 𝛽-hCG: beta-subunit of human chorionic gonadotropin; PAPP-A: pregnancy-associated plasma protein-A; MoM: multiple of the
median; LBW: low birth weight. Significant comparisons between unaffected pregnancies and preeclampsia cases (𝑃 < 0.05) using: ∗Mann-Whitney 𝑈 test,
aKruskal-Wallis test, and bPearson 𝜒2.
Our study provides evidence that both clinical forms of
EO-PE and LO-PE can be predicted using a combination of
maternal history and biomarkers assessed at first trimester
aneuploidy screening, in agreement with previous publi-
cations [9–15]. As expected, regression models applied for
prediction of the two forms of PE differed regarding which
variables were included and performance achieved for each
clinical form. However, these detection rates were modest,
suggesting that models need to be improved with new
information.
At false-positive rates of 5% and 10%, the detection rates
for EO-PE were 31.4% and 45.7%, respectively, which are
close to similar reported models [10, 12, 15]. Though EO-PE
prediction presented a better performance compared to LO-
PE, we must notice that its regression model only includes
maternal clinical data, excluding biochemical and ultrasound
markers. On the other hand, for LO-PE and overall PE
prediction, logistic regression analysis revealed significant
contributions from maternal factors, free 𝛽-hCG, CRL, and
NT, but not from PAPP-A.
Although EO-PE and LO-PE were associated with
decreased PAPP-A in the univariate analysis, this biomarker
was not included in any of the logistic models for PE
prediction. This could mean that the inclusion of PAPP-A in
the models did not add further significant information to the
one already provided by the others variables combined, hence
the potential added value of PAPP-A measurement could be
virtually negligible when used in combination with other
biomarkers. These results suggest that a combination of free
𝛽-hCG, NT, and CRL could be more useful in PE prediction
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Table 2: Logistic regressionmodels for prediction of PE, EO-PE and LO-PE bymaternal characteristics and aneuploidy screening biomarkers.
Variable PE EO-PE LO-PE
𝐵 𝑃-value 𝐵 𝑃-value 𝐵 𝑃-value
Chronic hypertension [if true] 0.870 0.014 1.519 0.004 0.050 0.012
Diabetes mellitus [if true] 1.428 0.000 1.649 0.000
Parity [if multiparous] −0.787 0.000 −1.201 0.008 −0.623 0.008
History of PE [if true] 3.952 0.000 3.201 0.001 3.668 0.000
Maternal age 0.039 0.026
Maternal weight (MoM, log) 6.159 0.000 7.108 0.000 5.834 0.000
CRL 0.027 0.010 0.036 0.003
NT −0.483 0.036 −0.592 0.026
Free 𝛽-hCG (MoM, log) 0.766 0.018 1.046 0.004
Constant −5.723 0.000 −4.951 0.000 −8.248 0.000
Note: Missing values or any variable not included in the table indicate that those variables were not selected for the final regression models by absence of
statistical significance. PE: preeclampsia; EO-PE: early-onset preeclampsia; LO-PE: late-onset preeclampsia.
Table 3: Detection rates and ROC results of logistic regression
models for prediction of PE, EO-PE, and LO-PE by maternal
characteristics and aneuploidy screening biomarkers.
Variable ROC AUC DR (FPR = 5%) DR (FPR = 10%)
PE 0.732 27.9 36.4
EO-PE 0.754 31.4 45.7
LO-PE 0.734 29.5 35.2
PE: preeclampsia; EO-PE: early-onset preeclampsia; LO-PE: late-onset
preeclampsia; AUC: area under the curve; DR: detection rate; FPR: false-
positive rate.
than PAPP-A alone. Our findings are supported by other
studies [11, 16, 17] that also found a significant association
between PE and PAPP-A that lost its significance when
combined with others biomarkers and therefore did not con-
tribute to PE prediction. Moreover, PAPP-A was significantly
related to LBW, unlike free 𝛽-hCG, NT, and CRL; previous
publications have shown inconsistent results regarding the
association of birth weight with these biomarkers, as some
studies reported a significant correlation [18, 19] and others
did not [14, 20, 21].
Our study presents some limitations related to its retro-
spective nature. First, serummeasurement of PAPP-A and 𝛽-
hCG was not performed by the same assay method for all
participants due to change of the analytical platform used
by the clinical chemistry laboratory during the study period;
however, this event was taken into consideration in the sta-
tistical analysis of data. Additionally, although several studies
[9–11, 15] have shown that mean arterial pressure (MAP) is
an important predictive variable for PE, data on maternal
arterial pressure at first trimester screening were not available
in clinical records. Furthermore, diagnosis of PE cases was
made by the treating physician, which could constitute a
potential source of bias. Nevertheless, it is the first study of
its kind conducted under routine clinical conditions in a Por-
tuguese obstetric population, reflecting the reality of nearly
five years of performing a first trimester prenatal screening
program.
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Figure 3: Variation of PAPP-A and 𝛽-hCG according to fetal weight
at delivery (LBW).
As the traditional approach for PE screening based
only on maternal demographic characteristics and medi-
cal history has shown to be insufficient [6], it is under
investigation which combinations of markers would improve
the performance of history-based screening. Ideal markers
for PE screening should be easily measured and integrated
within routine testing currently used as a part of prenatal
screening. Furthermore, it would be helpful to integrate PE
screening into existing analytical platforms to reduce costs,
equipment, and human resources. Moreover, those markers
should predict the risk in the first trimester of pregnancy,
thus creating a wide window of opportunity to imple-
ment preventive or prophylactic treatment strategies which
may facilitate normal placental development [22]. In this
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regard, biomarkers measured concurrently with testing for
aneuploidies meet these requirements.
This studywas conducted in a large unselected population
under routine clinical care conditions, which supports the
idea that screening for PE is feasible in obstetric populations
with low a priori risk. However, our results suggest that the
single inclusion of biomarkers currently used for aneuploidy
screening in the prediction models for PE cannot achieve
satisfactory detection rates and predictive values. Neverthe-
less, first trimester combined aneuploidy screening could be
improved by inclusion of other biomarkers implicated in
the pathophysiology of PE. Recent evidence suggests that
serum placental growth factor (PlGF) and uterine artery
pulsatility index (UtA Doppler) can be successfully included
in preeclampsia prediction models with promising results
[9–13, 15]. Although those results may be encouraging, it
is difficult to achieve generalizable conclusions and stan-
dardized cut-points at specific gestational ages due to diver-
gent study designs, population characteristics, and statistical
approaches. Therefore, performance of PE screening should
be validated in further large prospective studies.
Although the performance of such approach in Por-
tuguese population is unknown, we believe that screening for
PE could be successfully incorporated into routine prenatal
care for assessment of patient-specific risk for PE and there-
fore offer a window of opportunity for intervention in early
pregnancy.
4. Conclusion
Our findings support that both clinical forms of EO-PE and
LO-PE can be predicted using a combination of maternal
history and biomarkers assessed at first trimester aneuploidy
screening. However, detection rates were modest, suggesting
that the models need to be improved with additional markers
not included in current aneuploidy screening programs.
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